Key Takeaways
- • 342 cardiology clinics acquired by private equity firms over the past decade, with over 94% of acquisitions occurring between 2021 and 2023, signaling an accelerating trend despite industry skepticism about PE's long-term dominance in the specialty.
- • Medicare's 2020 rule permitting cardiac procedures in ambulatory surgery centers catalyzed PE interest in cardiology, enabling firms to capture value from lower-cost outpatient settings while addressing the prevalence and severity of cardiac disease in the U.S. population.
- • Systematic review of 55 publications demonstrates private equity ownership correlates with higher costs for patients and payers alongside mixed to harmful effects on quality of care, according to healthcare policy analysis.
- • Cardiologists express significant skepticism about private equity involvement, with an American College of Cardiology survey showing widespread familiarity with PE deals and concerns about potential overuse of cardiovascular procedures under PE ownership models.
- • Despite the headline-grabbing acquisition surge, private equity is unlikely to achieve dominant market penetration in cardiology, according to the story's central thesis, suggesting regulatory, clinical, and structural headwinds may limit long-term PE consolidation in the specialty.
Summary
Private equity firms have aggressively pursued acquisitions of cardiology practices over the past decade, with 342 clinics acquired during this period. However, the timing reveals a concentrated buying spree: over 94% of these acquisitions occurred between 2021 and 2023, reflecting a recent surge rather than a sustained long-term trend. This acceleration follows Medicare's 2020 rule change authorizing reimbursement for cardiac procedures in ambulatory surgery centers, fundamentally altering the economic calculus for PE investors seeking to deploy capital in healthcare.
The appeal of cardiology to private equity is straightforward and financially motivated. Cardiac disease represents both high prevalence and severity in the U.S. population, generating substantial procedure volumes and reimbursement opportunities. Unlike hospital-based cardiology, the shift toward outpatient and ambulatory settings creates lower-cost service delivery models where PE-backed operators can capture margin expansion. As Dr. Vikas Saini, president of the Lown Institute, stated in commentary on the trend: "The interest of private equity in cardiology is not humanitarian. They see dollar signs and they're going for them."
Yet despite the headline volume of deals, the structural sustainability of PE dominance in cardiology faces significant headwinds. Clinical and economic evidence presents a cautionary picture: a systematic review of 55 peer-reviewed publications examining private equity ownership in healthcare demonstrates consistent patterns of higher costs for both patients and payers, coupled with mixed-to-harmful effects on quality of care. An American College of Cardiology survey conducted earlier in 2026 revealed substantial cardiologist skepticism regarding PE involvement, with practitioners expressing concerns about potential overuse of cardiovascular procedures under PE ownership structures.
The regulatory and clinical environment further constrains PE's consolidation trajectory. Unlike lower-stakes specialties such as dermatology, ophthalmology, and gastroenterology—which have proven more amenable to PE acquisition—cardiology operates within stricter quality scrutiny, patient safety mandates, and clinical governance frameworks. While 50% of private practice cardiology has entered PE portfolios, this figure masks the reality that approximately 90% of cardiologists remain outside PE ownership, limiting the penetration pathway. Taken collectively, these factors suggest that despite the recent acquisition surge, private equity's long-term dominance in cardiology will likely remain constrained by clinical resistance, regulatory friction, and evidence-based concerns about care quality and cost escalation.
The appeal of cardiology to private equity is straightforward and financially motivated. Cardiac disease represents both high prevalence and severity in the U.S. population, generating substantial procedure volumes and reimbursement opportunities. Unlike hospital-based cardiology, the shift toward outpatient and ambulatory settings creates lower-cost service delivery models where PE-backed operators can capture margin expansion. As Dr. Vikas Saini, president of the Lown Institute, stated in commentary on the trend: "The interest of private equity in cardiology is not humanitarian. They see dollar signs and they're going for them."
Yet despite the headline volume of deals, the structural sustainability of PE dominance in cardiology faces significant headwinds. Clinical and economic evidence presents a cautionary picture: a systematic review of 55 peer-reviewed publications examining private equity ownership in healthcare demonstrates consistent patterns of higher costs for both patients and payers, coupled with mixed-to-harmful effects on quality of care. An American College of Cardiology survey conducted earlier in 2026 revealed substantial cardiologist skepticism regarding PE involvement, with practitioners expressing concerns about potential overuse of cardiovascular procedures under PE ownership structures.
The regulatory and clinical environment further constrains PE's consolidation trajectory. Unlike lower-stakes specialties such as dermatology, ophthalmology, and gastroenterology—which have proven more amenable to PE acquisition—cardiology operates within stricter quality scrutiny, patient safety mandates, and clinical governance frameworks. While 50% of private practice cardiology has entered PE portfolios, this figure masks the reality that approximately 90% of cardiologists remain outside PE ownership, limiting the penetration pathway. Taken collectively, these factors suggest that despite the recent acquisition surge, private equity's long-term dominance in cardiology will likely remain constrained by clinical resistance, regulatory friction, and evidence-based concerns about care quality and cost escalation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.